PFG Investments LLC Makes New $644,000 Investment in Insulet Co. (NASDAQ:PODD)

PFG Investments LLC bought a new position in shares of Insulet Co. (NASDAQ:PODD) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,760 shares of the medical instruments supplier’s stock, valued at approximately $644,000.

Other institutional investors have also recently bought and sold shares of the company. Capital Research Global Investors boosted its stake in Insulet by 19.7% in the 4th quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock worth $2,056,255,000 after purchasing an additional 1,556,455 shares during the period. Baillie Gifford & Co. acquired a new position in Insulet in the 4th quarter worth $263,144,000. Norges Bank acquired a new position in Insulet in the 4th quarter worth $227,655,000. William Blair Investment Management LLC boosted its stake in Insulet by 145.1% in the 3rd quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock worth $116,894,000 after purchasing an additional 433,884 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Insulet by 56.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 878,529 shares of the medical instruments supplier’s stock worth $190,623,000 after purchasing an additional 316,649 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on PODD shares. Stifel Nicolaus upped their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Piper Sandler cut their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Barclays cut their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.21.

Insulet Stock Performance

Shares of PODD stock traded up $4.07 on Monday, reaching $170.26. The stock had a trading volume of 602,109 shares, compared to its average volume of 859,181. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. The firm’s 50-day moving average is $171.09 and its two-hundred day moving average is $180.25. The firm has a market capitalization of $11.92 billion, a price-to-earnings ratio of 58.51, a P/E/G ratio of 2.99 and a beta of 0.98. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same period in the prior year, the firm earned $0.55 EPS. Insulet’s quarterly revenue was up 37.9% compared to the same quarter last year. On average, research analysts expect that Insulet Co. will post 3.08 EPS for the current fiscal year.

Insider Activity at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.47% of the stock is owned by company insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.